However, the authors went on to show that IL-10-producing ILCs in the kidney can be expanded by IL-2/anti-IL-2 complex (IL2C) treatment and mediate protective effects in the IRI-AKI model by downstream mechanisms similar to IL-25- or IL-33-elicited ILCs (Figure 1) (34), underlining the therapeutic potential of kidney ILCs in AKI. Here, IL10 is linked to acute kidney injury.